# The Guardian Science reports early CAR-T results for stiff person syndrome [Canonical reading](https://escapemeridian.com/readings/the-guardian-science-reports-early-car-t-results-for-stiff-6e8386e6) The Guardian Science reports early results from a Mayo Clinic trial of CAR-T cell therapy for stiff person syndrome (SPS), a rare autoimmune condition that can cause severe stiffness and painful muscle spasms. The treatment uses a patient’s own T cells, a type of immune cell, which are extracted and engineered to target disease-causing cells. Doctors say some participants improved enough to return to everyday activities; Jonathan Walden returned to work, while Shari St Germain described walking on a treadmill again. The article presents these changes as notable because, according to neurologist Anastasia Zekeridou, existing treatments can improve symptoms but very rarely restore patients’ previous level of function. These are early results, not evidence that the benefits will last: Zekeridou says whether improvements are sustained is the key question. Neurologist Sean Pittock says the findings may also point to possible uses in other autoimmune neurologic diseases, but stresses that much remains to be learned. The report does not provide the trial’s size or follow-up duration, so the extent and durability of the reported improvements cannot be assessed from this account. Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims. ## Original source The Guardian · Article Original source date: Nov 9, 2026 (2026-11-09T16:42:22.000Z). Date basis: Date stated by the publisher. Added to Escape Meridian: 2026-11-09T21:16:38.673Z. First observed: 2026-11-09T17:06:24.337Z. Retrieved: 2026-11-09T20:48:18.369Z. - [Medical breakthrough offers hope to people with same stiff person syndrome as Céline Dion](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Limits The article does not state the trial’s size or follow-up duration, limiting what can be assessed here about the extent and durability of the reported improvements. ## Open question Will the improvements reported in the trial be sustained over time? ## Source-stated The Guardian describes CAR-T cell therapy being tested for stiff person syndrome, using patients’ own engineered T cells to target disease-causing cells. > SPS patients’ own T cells, a type of immune cell, were extracted and engineered to wipe out disease-causing cells. - [Supporting source](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Source-stated Doctors at Mayo Clinic reported that some trial participants regained everyday abilities, including returning to work or hobbies. > with some even returning to work and resuming hobbies, according to doctors at the Mayo Clinic. - [Supporting source](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Source-stated Neurologist Anastasia Zekeridou said the degree of improvement was striking and that whether it lasts is the key question. > These early results are very encouraging, and the key question now is whether those improvements will be sustained over time. - [Supporting source](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Source-stated Neurologist Sean Pittock said the findings could have relevance beyond stiff person syndrome, while emphasizing that more remains to be learned. > There is still much we need to learn, but this opens an exciting new avenue for the field. - [Supporting source](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Source and contributor context Andrew Gregory · Article author These are credits stated by the source; they do not establish a profile match or authorship of every passage. ## Source media Media declared by the original publisher; availability checked separately from the editorial reading. - [Céline Dion smiling while clenching her hands in front of her. · The Guardian](https://i.guim.co.uk/img/media/b977ef32745f10c72ba6c3532a4afd8be410f6ef/0_0_5833_4667/master/5833.jpg?width=465&dpr=1&s=none&crop=none) ## Terms and references Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement. ## The Guardian Science The Guardian's science feed reports research, environment, and related public disputes. - [Explore this context](/entities/guardian-science) - [Reference](https://www.theguardian.com/science) - [Reference](https://www.theguardian.com/science/rss) ## TIME TIME is a news magazine publishing reporting on world affairs, business, technology and the workers behind digital services. - [Explore this context](/entities/time) - [Reference](https://time.com/) ## Editorial provenance Version 1. Publication ID: 06e08542-b3ca-48d8-84f4-39c1cb79ecc1. Prepared by gpt-6-luna; grounding review by gpt-6-luna. Source check: passed by anthropic/claude-opus-5.5 on 2026-11-09T21:16:38.673Z. This checks fidelity to the source, not whether its claims are independently true. Editorial selection: accept; reasons: material\_development. Observation: eed9b4d7f649d1f0b6ddf6e4f8e6c9b0fe642dae0b731fb0bf776a93834761af. Source text hash: 584b16a5c734bb8ddfa42fe701f6d707bf0bd5e87b8e4972c4c6328584ce1cdc. ## Revision and source-check history ### Version 1 — 2026-11-09T21:16:38.673Z The Guardian Science reports early results from a Mayo Clinic trial of CAR-T cell therapy for stiff person syndrome (SPS), a rare autoimmune condition that can cause severe stiffness and painful muscle spasms. The treatment uses a patient’s own T cells, a type of immune cell, which are extracted and engineered to target disease-causing cells. Doctors say some participants improved enough to return to everyday activities; Jonathan Walden returned to work, while Shari St Germain described walking on a treadmill again. The article presents these changes as notable because, according to neurologist Anastasia Zekeridou, existing treatments can improve symptoms but very rarely restore patients’ previous level of function. These are early results, not evidence that the benefits will last: Zekeridou says whether improvements are sustained is the key question. Neurologist Sean Pittock says the findings may also point to possible uses in other autoimmune neurologic diseases, but stresses that much remains to be learned. The report does not provide the trial’s size or follow-up duration, so the extent and durability of the reported improvements cannot be assessed from this account. ## Original source The Guardian · Article Original source date: Nov 9, 2026 (2026-11-09T16:42:22.000Z). Date basis: Date stated by the publisher. Added to Escape Meridian: 2026-11-09T21:16:38.673Z. First observed: 2026-11-09T17:06:24.337Z. Retrieved: 2026-11-09T20:48:18.369Z. - [Medical breakthrough offers hope to people with same stiff person syndrome as Céline Dion](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Limits The article does not state the trial’s size or follow-up duration, limiting what can be assessed here about the extent and durability of the reported improvements. ## Open question Will the improvements reported in the trial be sustained over time? ## Source-stated The Guardian describes CAR-T cell therapy being tested for stiff person syndrome, using patients’ own engineered T cells to target disease-causing cells. > SPS patients’ own T cells, a type of immune cell, were extracted and engineered to wipe out disease-causing cells. - [Supporting source](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Source-stated Doctors at Mayo Clinic reported that some trial participants regained everyday abilities, including returning to work or hobbies. > with some even returning to work and resuming hobbies, according to doctors at the Mayo Clinic. - [Supporting source](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Source-stated Neurologist Anastasia Zekeridou said the degree of improvement was striking and that whether it lasts is the key question. > These early results are very encouraging, and the key question now is whether those improvements will be sustained over time. - [Supporting source](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Source-stated Neurologist Sean Pittock said the findings could have relevance beyond stiff person syndrome, while emphasizing that more remains to be learned. > There is still much we need to learn, but this opens an exciting new avenue for the field. - [Supporting source](https://www.theguardian.com/science/2026/nov/09/medical-breakthrough-offers-hope-to-people-with-same-stiff-person-syndrome-as-celine-dion) ## Source and contributor context Andrew Gregory · Article author These are credits stated by the source; they do not establish a profile match or authorship of every passage. ## Source media Media declared by the original publisher; availability checked separately from the editorial reading. - [Céline Dion smiling while clenching her hands in front of her. · The Guardian](https://i.guim.co.uk/img/media/b977ef32745f10c72ba6c3532a4afd8be410f6ef/0_0_5833_4667/master/5833.jpg?width=465&dpr=1&s=none&crop=none) ## Terms and references Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement. ## The Guardian Science The Guardian's science feed reports research, environment, and related public disputes. - [Explore this context](/entities/guardian-science) - [Reference](https://www.theguardian.com/science) - [Reference](https://www.theguardian.com/science/rss) ## TIME TIME is a news magazine publishing reporting on world affairs, business, technology and the workers behind digital services. - [Explore this context](/entities/time) - [Reference](https://time.com/) ## Editorial provenance Version 1. Publication ID: 06e08542-b3ca-48d8-84f4-39c1cb79ecc1. Prepared by gpt-6-luna; grounding review by gpt-6-luna. Source check: passed by anthropic/claude-opus-5.5 on 2026-11-09T21:16:38.673Z. This checks fidelity to the source, not whether its claims are independently true. Editorial selection: accept; reasons: material\_development. Observation: eed9b4d7f649d1f0b6ddf6e4f8e6c9b0fe642dae0b731fb0bf776a93834761af. Source text hash: 584b16a5c734bb8ddfa42fe701f6d707bf0bd5e87b8e4972c4c6328584ce1cdc. ### passed — 2026-11-09T21:16:38.673Z — anthropic/claude-opus-5.5 Publication: 06e08542-b3ca-48d8-84f4-39c1cb79ecc1 attribution — pass: The reading attributes the report to The Guardian Science, the results to Mayo Clinic doctors, and the quotes to Anastasia Zekeridou and Sean Pittock. Each assertion stays with its speaker, and patient experiences are attributed to the named patients. Calling Pittock a neurologist fits his stated role as chair of Mayo Clinic's neurology department. > Dr Sean Pittock, chair of the department of neurology at Mayo Clinic, said summary — pass: The reading leads with the development and explains SPS, CAR-T and T cells in plain language. It conveys the significance Zekeridou gives: patients rarely regain previous function with existing treatments. It also keeps the patients' human stakes and the source's hopeful but cautious tone. The question follows Zekeridou's stated key question. Omitting the Jama Neurology publication venue is minor and does not distort meaning. > With existing treatments, we may be able to improve symptoms, but we very rarely see patients return to their previous level of function. date — pass: The originalPublished value of 2026-11-09T16:42:22Z comes from the publisher page. It matches the feed entry and the article URL date path, and no earlier publication is indicated. support — pass: Every claim matches the source text. The engineered T cells, return to work and hobbies, Zekeridou's quote on sustainability and Pittock's broader-potential caveat are all stated there. The limitation about trial size and follow-up is accurate, because the article gives neither. The reading does not overstate the results as proven or durable. > There is still much we need to learn, but this opens an exciting new avenue for the field. media — pass: The selected media is the verified direct link to the original Guardian article. It is the most direct way to access the source. ## Recorded references Explicit citations in public readings and public file attachments to this reading. Shared topics are not citations. Other artifact types need an explicit reference adapter. No public references recorded here yet. [Reference data (JSON)](/readings/6e8386e621485000a5b9e49fe45403962dfe362be4af455c9b246c85c85ccd4d/references.json) ## Corrections and challenges [Send a correction or an opposing source](https://escapemeridian.com/corrections/) [JSON record](https://escapemeridian.com/readings/the-guardian-science-reports-early-car-t-results-for-stiff-6e8386e6.json)